Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Moodys
US Army
Accenture
Julphar
Express Scripts
Cerilliant
AstraZeneca
Queensland Health
Fuji

Generated: May 26, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,627,816

« Back to Dashboard

Which drugs does patent 8,627,816 protect, and when does it expire?

Patent 8,627,816 protects EVZIO and is included in two NDAs.

This patent has thirty-two patent family members in ten countries.
Summary for Patent: 8,627,816
Title:Medicament delivery device for administration of opioid antagonists including formulations for naloxone
Abstract: Medicament delivery devices for administration of opioid antagonists are described herein. In some embodiments, an apparatus includes a housing, a medicament container disposed within the housing and an energy storage member disposed within the housing. The medicament container is filled with a naloxone composition that includes naloxone or salts thereof, a tonicity-adjusting agent, and a pH adjusting agent, whereby the osmolality of the naloxone composition ranges from about 250-350 mOsm and the pH ranges from about 3-5. The energy storage member is configured to produce a force to deliver the naloxone composition.
Inventor(s): Edwards; Eric S. (Midlothian, VA), Edwards; Evan T. (Gordonsville, VA), Licata; Mark J. (Doswell, VA), Blondino; Frank E. (Henrico, VA)
Assignee: Intelliject, Inc. (Richmond, VA)
Application Number:13/036,720
Patent Claim Types:
see list of patent claims
Composition; Device; Delivery;

Drugs Protected by US Patent 8,627,816

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Kaleo Inc EVZIO naloxone hydrochloride SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS 205787-001 Apr 3, 2014 DISCN Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Kaleo Inc EVZIO naloxone hydrochloride SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS 209862-001 Oct 19, 2016 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 8,627,816

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,084,849 Medicament delivery devices for administration of a medicament within a prefilled syringe ➤ Sign Up
8,939,943 Medicament delivery device for administration of opioid antagonists including formulations for naloxone ➤ Sign Up
9,814,838 Medicament delivery device for administration of opioid antagonists including formulations for naloxone ➤ Sign Up
9,474,869 Medicament delivery device for administration of opioid antagonists including formulations for naloxone ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Johnson and Johnson
US Department of Justice
Merck
Cerilliant
Dow
Deloitte
McKinsey
QuintilesIMS
Chinese Patent Office

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.